ArticleInternational journal of molecular sciences2023
CRISPR-Cas9-Mediated Correction of
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Kidney organoids as models for hereditary kidney diseases: Toward precision medicine (Review).Experimental and therapeutic medicine · 2026Review
- Gene modification: Exploring the potential in treating kidney diseases.Pharmacological research · 2026Review
- Review
- Advancing the understanding of alveolar regeneration: Global research trends, thematic evolution, and emerging frontiers.Regenerative therapy · 2025Review
- Modeling of kidney allograft rejection using hiPSC-derived kidney organoids and HLA-mismatched PBMCs: an in vitro co-culture system.Cellular and molecular life sciences : CMLS · 2025Article
- Review
- Landscape of human organoids: Ideal model in clinics and research.Innovation (Cambridge (Mass.)) · 2024Review
- Modeling ofCells · 2023Article
- Mini-organs with big impact: Organoids in liver cancer studies.Oncology research · 2023Review
- Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis.Kidney diseases (Basel, Switzerland)Review
- Progress of Induced Pluripotent Stem Cell-Derived Renal Organoids in Clinical Application.Kidney diseases (Basel, Switzerland)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The aim of this study is to explore the possibility of modeling Gitelman's disease (GIT) with human-induced pluripotent stem cell (hiPSC)-derived kidney organoids and to test whether gene correction using CRISPR/Cas9 can rescue the disease phenotype of GIT. To model GIT, we used the hiPSC line CMCi002 (CMC-GIT-001), generated using PBMCs from GIT patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.